A false-colored micrograph showing swirls of yellow, red, and magenta cells
Cross-Resistance: One Cancer Therapy Can Undermine the Next
Targeted cancer therapy may jeopardize the effectiveness of subsequent immunotherapy by reducing dendritic cell numbers and activation, according to study of mice and patient samples.
Cross-Resistance: One Cancer Therapy Can Undermine the Next
Cross-Resistance: One Cancer Therapy Can Undermine the Next

Targeted cancer therapy may jeopardize the effectiveness of subsequent immunotherapy by reducing dendritic cell numbers and activation, according to study of mice and patient samples.

Targeted cancer therapy may jeopardize the effectiveness of subsequent immunotherapy by reducing dendritic cell numbers and activation, according to study of mice and patient samples.

targeted therapy
Mutant RAS Proteins Team Up for Oncogenicity
Jim Daley | Apr 1, 2018
Mice with cancer whose KRAS proteins couldn’t link together had much better survival outcomes than those whose oncogenic mutant paired with wild-type KRAS.
Clinical Matchmaker
Kate Yandell | Jun 1, 2015
Enrolling the right patient population could be key to a successful clinical trial.